1.    PRODUCT OVERVIEW

1.1.  MARKET DEFINITION

1.2.  SCOPE OF THE MARKET

1.2.1.    MARKETS COVERED

1.2.2.    YEARS CONSIDERED FOR STUDY

1.2.3.    KEY MARKET SEGMENTATIONS

2.    RESEARCH METHODOLOGY

2.1.  OBJECTIVE OF THE STUDY

2.2.  BASELINE METHODOLOGY

2.3.  KEY INDUSTRY PARTNERS

2.4.  MAJOR ASSOCIATION AND SECONDARY SOURCES

2.5.  FORECASTING METHODOLOGY

2.6.  DATA TRIANGULATION & VALIDATION

2.7.  ASSUMPTIONS AND LIMITATIONS

3.    EXECUTIVE SUMMARY

3.1.  OVERVIEW OF THE MARKET

3.2.  OVERVIEW OF KEY MARKET SEGMENTATIONS

3.3.  OVERVIEW OF KEY MARKET PLAYERS

3.4.  OVERVIEW OF KEY REGIONS/COUNTRIES

3.5.  OVERVIEW OF MARKET DRIVERS, CHALLENGES, TRENDS

4.    VOICE OF CUSTOMER

5.     JAPAN CANCER SUPPORTIVE CARE MARKET OUTLOOK

5.1.  MARKET SIZE & FORECAST

5.1.1.    BY VALUE

5.2.  MARKET SHARE & FORECAST

5.2.1.    BY THERAPEUTICS CLASS (G-CSFS (GRANULOCYTE-COLONY STIMULATING FACTORS), ESAS (ERYTHROPOIESIS STIMULATING AGENTS), ANTI-EMETICS, BISPHOSPHONATES, OPIOIDS, NSAIDS, OTHERS)

5.2.2.    BY REGION

5.2.3.    BY COMPANY (2024)

5.3.  MARKET MAP

6.    HOKKAIDO CANCER SUPPORTIVE CARE MARKET OUTLOOK

6.1.  MARKET SIZE & FORECAST

6.1.1.    BY VALUE

6.2.  MARKET SHARE & FORECAST

6.2.1.    BY THERAPEUTICS CLASS

7.    TOHOKU CANCER SUPPORTIVE CARE MARKET OUTLOOK

7.1.  MARKET SIZE & FORECAST

7.1.1.    BY VALUE

7.2.  MARKET SHARE & FORECAST

7.2.1.    BY THERAPEUTICS CLASS

8.    KANTO CANCER SUPPORTIVE CARE MARKET OUTLOOK

8.1.  MARKET SIZE & FORECAST

8.1.1.    BY VALUE

8.2.  MARKET SHARE & FORECAST

8.2.1.    BY THERAPEUTICS CLASS

9.    CHUBU CANCER SUPPORTIVE CARE MARKET OUTLOOK

9.1.  MARKET SIZE & FORECAST

9.1.1.    BY VALUE

9.2.  MARKET SHARE & FORECAST

9.2.1.    BY THERAPEUTICS CLASS

10. KANSAI CANCER SUPPORTIVE CARE MARKET OUTLOOK

10.1.   MARKET SIZE & FORECAST        

10.1.1. BY VALUE

10.2.   MARKET SHARE & FORECAST

10.2.1. BY THERAPEUTICS CLASS

11. CHUGOKU CANCER SUPPORTIVE CARE MARKET OUTLOOK

11.1.   MARKET SIZE & FORECAST        

11.1.1. BY VALUE

11.2.   MARKET SHARE & FORECAST

11.2.1. BY THERAPEUTICS CLASS

12. SHIKOKU CANCER SUPPORTIVE CARE MARKET OUTLOOK

12.1.   MARKET SIZE & FORECAST        

12.1.1. BY VALUE

12.2.   MARKET SHARE & FORECAST

12.2.1. BY THERAPEUTICS CLASS

13. KYUSHU CANCER SUPPORTIVE CARE MARKET OUTLOOK

13.1.   MARKET SIZE & FORECAST        

13.1.1. BY VALUE

13.2.   MARKET SHARE & FORECAST

13.2.1. BY THERAPEUTICS CLASS

14. MARKET DYNAMICS

14.1.   DRIVERS

14.2.   CHALLENGES

15. MARKET TRENDS & DEVELOPMENTS

15.1.   RECENT DEVELOPMENTS

15.2.   PRODUCT LAUNCHES

15.3.   MERGERS & ACQUISITIONS

16.  JAPAN CANCER SUPPORTIVE CARE MARKET: SWOT ANALYSIS

17. COMPETITIVE LANDSCAPE

17.1.   AMGEN, INC.

17.1.1.       BUSINESS OVERVIEW

17.1.2.       PRODUCT & SERVICE OFFERINGS

17.1.3.       RECENT DEVELOPMENTS

17.1.4.       KEY PERSONNEL

17.1.5.       FINANCIALS (IF LISTED)

17.1.6.       SWOT ANALYSIS

17.2.   MERCK & CO., INC.

17.3.   JOHNSON & JOHNSON SERVICES, INC.

17.4.   HERON THERAPEUTICS, INC.

17.5.   NOVARTIS AG

17.6.   GSK PLC

17.7.   F. HOFFMANN-LA ROCHE LTD.

17.8.   HELSINN HEALTHCARE SA

18. STRATEGIC RECOMMENDATIONS

19. ABOUT US & DISCLAIMER